With the World Health Organisation predicting millions will die due to global antimicrobial resistance (AMR), Reactive Oxygen® technology is a solution to meet the global AMR threat, improve patient outcomes and save lives. To date, in tests in the laboratory and on patients, no Gram-positive or Gram-negative bacteria, including multi-drug resistant strains have survived the contact with Reactive Oxygen® technology.

In partnership with world-leading researchers at British universities and teaching hospitals, MHL is developing the Reactive Oxygen® technology platform to take biotechnology into the heart of where antibiotics are increasingly failing. Our current focus is on developing a pharmaceutical product to fight infection and stimulate healing in Complex Polymicrobial Skin Lesions (CPSL).

People per year

die from AMR

0 million
by 2025

could die annually
without action


annual cost of AMR
to the NHS